Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Sarcoma 3Neoplasms 2Neoplasm Metastasis 2Wilms Tumor 1Uterine Cervical Neoplasms 1Osteosarcoma 1Neuroblastoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Radiosurgery 10Temozolomide 6Magnetic Resonance Spectroscopy 6pembrolizumab 3Trastuzumab 3Radiation 3fluciclovine F-18 2cabazitaxel 2Surgical Procedures, Operative 2Specimen Handling 2Radiotherapy 2Magnetic Resonance Imaging 2Erlotinib Hydrochloride 2Carboplatin 2Bevacizumab 2Aminolevulinic Acid 2tucatinib 1thymoglobulin 1tepotinib 1temsirolimus 1sodium thiosulfate 1ribociclib 1pazopanib 1patritumab deruxtecan 1palbociclib 1osimertinib 1neratinib 1lenvatinib 1irinotecan sucrosofate 1gancotamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Brain Neoplasms × pazopanib × Clear all
NCT01130623 2017-07-02

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
CNSGenitourinarySarcoma

Brain Neoplasms, Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡